Analysts Set Humacyte, Inc. (NASDAQ:HUMA) Price Target at $8.60

Shares of Humacyte, Inc. (NASDAQ:HUMA) have been given a consensus recommendation of “Buy” by the six ratings firms that are currently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $8.60.

Several equities research analysts recently issued reports on the company. Benchmark reiterated a “buy” rating and issued a $15.00 price objective on shares of Humacyte in a report on Thursday, September 5th. EF Hutton Acquisition Co. I raised Humacyte to a “strong-buy” rating in a research note on Monday. Cantor Fitzgerald reissued an “overweight” rating and issued a $7.00 price objective on shares of Humacyte in a research note on Tuesday, July 2nd. Finally, BTIG Research lifted their target price on shares of Humacyte from $8.00 to $11.00 and gave the stock a “buy” rating in a research note on Monday, July 15th.

Humacyte Price Performance

Humacyte stock opened at $5.62 on Tuesday. The stock has a market capitalization of $669.25 million, a P/E ratio of -5.62 and a beta of 1.47. The company’s fifty day moving average price is $6.93 and its 200 day moving average price is $5.53. The company has a debt-to-equity ratio of 0.61, a quick ratio of 5.41 and a current ratio of 5.41. Humacyte has a 1 year low of $1.96 and a 1 year high of $9.97.

Humacyte (NASDAQ:HUMA) last announced its earnings results on Tuesday, August 13th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.04). As a group, equities research analysts anticipate that Humacyte will post -1.09 earnings per share for the current fiscal year.

Insider Transactions at Humacyte

In related news, Director Kathleen Sebelius sold 5,182 shares of the stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $5.40, for a total value of $27,982.80. Following the completion of the sale, the director now owns 40,276 shares of the company’s stock, valued at $217,490.40. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other Humacyte news, CFO Dale A. Sander sold 39,389 shares of Humacyte stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $6.68, for a total transaction of $263,118.52. Following the transaction, the chief financial officer now directly owns 2,000 shares of the company’s stock, valued at $13,360. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Kathleen Sebelius sold 5,182 shares of the business’s stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $5.40, for a total transaction of $27,982.80. Following the completion of the transaction, the director now owns 40,276 shares in the company, valued at $217,490.40. The disclosure for this sale can be found here. Insiders have sold a total of 1,084,153 shares of company stock worth $6,869,996 in the last ninety days. Insiders own 23.10% of the company’s stock.

Institutional Trading of Humacyte

Several institutional investors have recently made changes to their positions in the company. Endowment Wealth Management Inc. lifted its holdings in Humacyte by 3.1% in the second quarter. Endowment Wealth Management Inc. now owns 100,518 shares of the company’s stock valued at $482,000 after acquiring an additional 3,000 shares during the last quarter. nVerses Capital LLC purchased a new stake in Humacyte in the second quarter valued at $28,000. China Universal Asset Management Co. Ltd. raised its position in Humacyte by 65.9% in the first quarter. China Universal Asset Management Co. Ltd. now owns 19,883 shares of the company’s stock valued at $62,000 after purchasing an additional 7,897 shares during the period. The Manufacturers Life Insurance Company lifted its stake in shares of Humacyte by 32.5% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 34,919 shares of the company’s stock valued at $168,000 after purchasing an additional 8,557 shares during the last quarter. Finally, Victory Capital Management Inc. purchased a new position in shares of Humacyte during the 4th quarter worth $29,000. Hedge funds and other institutional investors own 44.71% of the company’s stock.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.